Improved Measurement of Treatment Effect in Multiple Sclerosis Clinical Trials
This decision analytical model study applies restricted mean survival time as a measure of treatment effect in 2 randomized clinical trials assessing disease-modifying treatments vs placebo in patients with progressive multiple sclerosis.
Authors
- Francesca Bovis (ORCID: https://orcid.org/0000-0002-3823-4000)
- Irene Schiavetti (ORCID: https://orcid.org/0000-0002-5460-2977)
- Alessio Signori (ORCID: https://orcid.org/0000-0001-6289-9144)
- Maria Pia Sormani (ORCID: https://orcid.org/0000-0001-6892-104X)
- Noemi Montobbio (ORCID: https://orcid.org/0000-0003-0302-393X)
- Marta Ponzano (ORCID: https://orcid.org/0000-0003-4091-4686)
- Maurizio Fedriga (ORCID: https://orcid.org/0009-0009-3435-7802)
Institutions
- Ospedale Policlinico San Martino (IT)
- University of Genoa (IT)
Publication Details
- Journal
- JAMA Neurology
- Published
- 2024-12-23
- DOI
- https://doi.org/10.1001/jamaneurol.2024.4396
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00